Danaher Co. (DHR) Receives $93.55 Consensus Price Target from Analysts

Shares of Danaher Co. (NYSE:DHR) have been assigned a consensus rating of “Buy” from the nineteen ratings firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $93.55.

Several research firms recently issued reports on DHR. Cowen reiterated a “buy” rating and issued a $90.00 price target on shares of Danaher in a report on Wednesday, October 4th. J P Morgan Chase & Co restated an “overweight” rating and set a $95.00 target price on shares of Danaher in a report on Friday, September 8th. Robert W. Baird raised their target price on Danaher from $87.00 to $97.00 and gave the stock an “outperform” rating in a report on Friday, October 20th. Zacks Investment Research upgraded Danaher from a “hold” rating to a “buy” rating and set a $97.00 target price on the stock in a report on Thursday, October 5th. Finally, Goldman Sachs Group restated a “neutral” rating and set a $83.00 target price on shares of Danaher in a report on Tuesday, September 26th.

In other news, Director Donald J. Ehrlich sold 10,578 shares of Danaher stock in a transaction that occurred on Tuesday, October 24th. The stock was sold at an average price of $90.82, for a total transaction of $960,693.96. Following the completion of the transaction, the director now directly owns 104,621 shares in the company, valued at approximately $9,501,679.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Daniel Raskas sold 37,870 shares of Danaher stock in a transaction that occurred on Thursday, November 16th. The stock was sold at an average price of $93.33, for a total value of $3,534,407.10. The disclosure for this sale can be found here. Insiders have sold a total of 273,810 shares of company stock worth $25,218,813 in the last ninety days. Insiders own 12.20% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in DHR. Parametric Portfolio Associates LLC raised its holdings in Danaher by 6.2% in the 3rd quarter. Parametric Portfolio Associates LLC now owns 1,612,412 shares of the conglomerate’s stock valued at $138,313,000 after acquiring an additional 94,344 shares in the last quarter. AXA raised its holdings in shares of Danaher by 1.9% during the 3rd quarter. AXA now owns 906,949 shares of the conglomerate’s stock worth $77,798,000 after buying an additional 16,565 shares in the last quarter. Shelton Capital Management raised its holdings in shares of Danaher by 13.9% during the 3rd quarter. Shelton Capital Management now owns 9,666 shares of the conglomerate’s stock worth $829,000 after buying an additional 1,181 shares in the last quarter. Chicago Partners Investment Group LLC raised its holdings in shares of Danaher by 394.1% during the 3rd quarter. Chicago Partners Investment Group LLC now owns 3,953 shares of the conglomerate’s stock worth $339,000 after buying an additional 3,153 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC acquired a new position in shares of Danaher during the 3rd quarter worth $389,000. Institutional investors and hedge funds own 76.32% of the company’s stock.

Shares of Danaher (NYSE DHR) traded down $1.30 during mid-day trading on Monday, hitting $92.85. The stock had a trading volume of 2,839,601 shares, compared to its average volume of 2,616,768. The company has a quick ratio of 1.00, a current ratio of 1.43 and a debt-to-equity ratio of 0.42. The company has a market capitalization of $65,490.00, a PE ratio of 24.08, a PEG ratio of 2.23 and a beta of 1.02. Danaher has a 12 month low of $77.66 and a 12 month high of $94.82.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Thursday, October 19th. The conglomerate reported $1.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.95 by $0.05. The business had revenue of $4.53 billion for the quarter, compared to analysts’ expectations of $4.47 billion. Danaher had a return on equity of 11.29% and a net margin of 13.36%. The firm’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same quarter last year, the business earned $0.87 earnings per share. equities research analysts forecast that Danaher will post 3.99 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, January 26th. Shareholders of record on Friday, December 29th will be given a dividend of $0.14 per share. This represents a $0.56 annualized dividend and a dividend yield of 0.60%. The ex-dividend date is Thursday, December 28th. Danaher’s dividend payout ratio (DPR) is 16.67%.

WARNING: This piece was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://stocknewstimes.com/2017/12/14/danaher-co-dhr-receives-93-55-consensus-price-target-from-analysts.html.

Danaher Company Profile

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

Analyst Recommendations for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply